相似化合物
848243-23-2 1150114-42-3 163105-90-6上下游产品
CAS号14529-53-4 2-乙氧基吡啶合成工艺路线路线简述
- 合成目标产物 2-Ethoxy-3-Pyridineboronic Acid 主要起始原料 2-Ethoxypyridine
- 14529-53-4 = 854373-97-0
反应条件:1.1 Reagents: Lithium Diisopropylamide Solvents: Tetrahydrofuran,Hexane; -50 °C; 1 H,-50 °C1.2 Reagents: (T-4)-Hydrotris(2-Propanolato)Borate(1-); -50 °C; 1 H,-50 °C; -50 °C -> -10 °C1.3 Reagents: Water
标题:2-Ethoxy-3-Pyridylboronic Acid: A Versatile Reagent For The Synthesis Of Highly-Functionalized 3-Aryl/heteroaryl-Pyridines Via Suzuki Cross-Coupling Reactions
作者:Thompson,Amy E.; Et Al
参考文献:Tetrahedron 日期:2005 卷标:61(21) 页码:5131-5135
2-乙氧基吡啶置于lithium Diisopropyl Amide,硼酸三异丙酯体系中,用 四氢呋喃,正己烷 作为反应溶剂,化学反应 1.0H,以70%的收率获得产物2-乙氧基吡啶-3-硼酸
参考文献:2-乙氧基-3-吡啶基硼酸:通过铃木交叉偶联反应合成高度官能化的3-芳基/杂芳基-吡啶的通用试剂
标题:2-乙氧基-3-吡啶基硼酸:通过铃木交叉偶联反应合成高度官能化的3-芳基/杂芳基-吡啶的通用试剂
摘要:本文描述了在商业上可行的合成和分离的ca上的2-乙氧基-3-吡啶基硼酸.经由定向70克规模邻上容易获得的2-乙氧基吡啶-Metalation反应.在钯催化的suzuki-Miyaura条件下,2-乙氧基-3-吡啶基硼酸与选定的芳基/杂芳基卤化物的一系列有效交叉偶联反应可高产率产生新型的2-乙氧基-3-芳基/杂芳基吡啶(杂芳基=吡啶基,嘧啶基,吡唑基).2-乙氧基-3-吡啶基硼酸的x射线晶体结构表明,硼酸基团与相邻的乙氧基取代基一起参与分子内的o-h⋯o键和一个分子间的o-h⋯n键.
DOI:10.1016/j.Tet.2005.02.070
海关参考信息
- 2933310010-吡啶
2901100000-饱和无环烃
2909199090-其他醚及其衍生物
2939800000-其他生物碱 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12150934-B2
优先权日:2016-11-30
标 题 :Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
发明人:SIDDIQUI ARSHAD M; CIBLAT STEPHANE; CONSTANTINEAU-FORGET LEA; GRAND-MAITRE CHANTAL; GUO XIANGYU; SRIVASTAVA SANJAY; SHIPPS GERALD W; COOPER ALAN B; OZA VIBHA; KOSTURA MATTHEW W; LUTHER MICHAEL; LEVINE JEDD
权利人:BANTAM PHARMACEUTICAL LLC
摘要:Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by “aâ€?, R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.